Understanding Recommendations for HER2+ Breast Cancer Treatment in Canada
HER2-positive (HER2+) breast cancer is a more aggressive form of breast cancer, affecting about 14% of patients. Thankfully, breakthroughs in targeted therapies over the years have improved outcomes for those living with this condition. But even with these advances, gaps remain in how treatments are provided across Canada. That’s where new national recommendations come in to ensure all patients, regardless of location, receive the best care possible.
Research Excellence, Active Leadership (REAL) Canadian Breast Cancer Alliance, working with Breast Cancer Canada and a team of leading oncologists, developed these consensus recommendations. The goal? To guide healthcare professionals and policymakers on the best ways to treat HER2+ breast cancer—both in its early stages and for patients with advanced or metastatic cancer.
What Does This Mean for You?
These new recommendations aren’t just technical guidelines—they represent the collective voice of experts and patient advocates working together. They ensure that:
- Treatment is evidence-based: Every recommendation is rooted in the latest research to maximize care effectiveness.
- Care is consistent across Canada: Patients will have access to the same standard of care, no matter where they live.
- Patients with complex cases are included: Special focus is given to those with brain metastases, where treatment has traditionally been limited.
Key Takeaways from the Recommendations
The recommendations cover three major areas:
- Early-stage HER2+ breast cancer: Strategies to prevent recurrence when cancer is detected early.
- Metastatic HER2+ breast cancer: Guidance to manage advanced cases and extend survival.
- Patients with brain metastases: Specific recommendations to treat cancer that has spread to the brain, addressing a key challenge for HER2+ patients.
These recommendations were developed using the Delphi process, where experts participated in multiple rounds of anonymous voting to reach consensus. This ensures that each recommendation reflects the shared expertise of top oncologists across the country.
Why Do These Recommendations Matter?
HER2+ breast cancer requires precision treatment, and these recommendations help oncologists make informed decisions tailored to each patient’s unique situation. They also provide a unified voice to advocate for better healthcare policies—ensuring patients receive timely access to innovative therapies.
By aligning practices and ensuring equal access to care, these recommendations represent an important step in closing treatment gaps across Canada.
To learn more about REAL Canadian Breast Cancer Alliance, please visit:
https://realalliance.ca/resources/
For a deeper dive into the technical aspects of the recommendations, check out the full article in Current Oncology :
National Consensus Recommendations for HER2+ Breast Cancer Treatment
These recommendations are a powerful tool to improve care—and ultimately, outcomes—for Canadians affected by this aggressive form of breast cancer.
